

Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition

Sm N. Udden, ... , Cheng-Ming Chiang, Prasanna G. Alluri

JCI Insight. 2022. <https://doi.org/10.1172/jci.insight.151851>.

Research In-Press Preview Oncology

Acquired mutations in the ligand-binding domain (LBD) of the gene encoding Estrogen Receptor alpha (*ESR1*) are a common mechanism of endocrine therapy resistance in metastatic ER-positive breast cancer patients. *ESR1* Y537S mutation, in particular, is associated with development of resistance to most endocrine therapies used to treat breast cancer. Employing a high-throughput screen of nearly 1200 Federal Drug Administration (FDA)-approved drugs, we show that OTX015, a bromodomain and extraterminal domain (BET) inhibitor, is one of the top suppressors of *ESR1* mutant cell growth. OTX015 was more efficacious than fulvestrant, a selective ER degrader, in inhibiting *ESR1* mutant xenograft growth. When combined with abemaciclib, a CDK4/6 inhibitor, OTX015 induced more potent tumor regression than current standard-of-care treatment of abemaciclib+fulvestrant. OTX015 has preferential activity against Y537S mutant breast cancer cells and blocks their clonal selection in competition studies with wild-type cells. Thus, BET inhibition has the potential to both prevent and overcome *ESR1* mutant-induced endocrine therapy resistance in breast cancer.

Find the latest version:

<https://jci.me/151851/pdf>



Targeting *ESR1* Mutation-Induced “Transcriptional Addiction” in Breast Cancer with BET Inhibition

Sm N. Udden^{1, #}, Qian Wang^{1, #}, Sunil Kumar^{2,3}, Venkat S. Malladi⁴, Shwu-Yuan Wu^{5,6}, Shuguang Wei⁵, Bruce A. Posner⁵, Sophie Geboers⁵, Noelle S. Williams⁵, Yulun Liu⁷, Jayesh K. Sharma¹, Ram S. Mani^{6,8}, Srinivas Malladi^{6,8}, Karla Parra⁹, Mia Hofstad⁹, Ganesh V. Raj^{6,9}, Jose M. Larios¹⁰, Reshma Jagsi¹¹, Max S. Wicha¹², Ben Ho Park¹³, Gaorav P. Gupta^{2,3}, Arul M. Chinnaiyan¹⁴, Cheng-Ming Chiang^{5,6,15}, Prasanna G. Alluri^{1,6,*}

These authors contributed equally to this work

¹ Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX

² Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC

³ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

⁴ Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX

⁵ Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX

⁶ Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

⁷ Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX

⁸ Department of Pathology, UT Southwestern Medical Center, Dallas, TX

⁹ Department of Urology, UT Southwestern Medical Center, Dallas, TX

¹⁰ Ascension Providence Hospital, Southfield, MI

¹¹ Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

¹² Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

¹³ Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN

¹⁴ Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI

¹⁵ Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX

* Address correspondence to: Prasanna G. Alluri, MD, PhD, Department of Radiation Oncology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, 2280 Inwood Rd., Dallas TX 75390-9303, USA.

Tel: (214) 648-8941; Email: Prasanna.Alluri@UTSouthwestern.edu

Running title: Targeting *ESR1* mutant breast cancer

Abstract

Acquired mutations in the ligand-binding domain (LBD) of the gene encoding Estrogen Receptor alpha (*ESR1*) are a common mechanism of endocrine therapy resistance in metastatic ER-positive breast cancer patients. *ESR1* Y537S mutation, in particular, is associated with development of resistance to most endocrine therapies used to treat breast cancer. Employing a high-throughput screen of nearly 1200 Federal Drug Administration (FDA)-approved drugs, we show that OTX015, a bromodomain and extraterminal domain (BET) inhibitor, is one of the top suppressors of *ESR1* mutant cell growth. OTX015 was more efficacious than fulvestrant, a selective ER degrader, in inhibiting *ESR1* mutant xenograft growth. When combined with abemaciclib, a CDK4/6 inhibitor, OTX015 induced more potent tumor regression than current standard-of-care treatment of abemaciclib+fulvestrant. OTX015 has preferential activity against Y537S mutant breast cancer cells and blocks their clonal selection in competition studies with wild-type cells. Thus, BET inhibition has the potential to both prevent and overcome *ESR1* mutant-induced endocrine therapy resistance in breast cancer.

Introduction

Approximately 75% of all breast cancers express Estrogen Receptor alpha ($ER\alpha$) and endocrine therapies, which block $ER\alpha$ signaling, are the mainstay of systemic treatment for patients with such cancers (1). Endocrine therapies significantly reduce the incidence, recurrence and mortality in patients with ER-positive breast cancers (2). However, nearly all patients with metastatic disease ultimately become refractory to all endocrine therapies (3). Thus, endocrine therapy resistance is the primary obstacle to effective treatment of metastatic, ER-positive breast cancer patients.

Acquired mutations in the ligand-binding domain (LBD) of the gene encoding $ER\alpha$ (*ESR1*) are one of the most common mechanisms of endocrine therapy resistance in metastatic, ER-positive breast cancer patients (4-7). *ESR1* mutations are rare in treatment-naïve primary tumors and arise under selective pressure of anti-estrogen therapy (4, 5). Nearly a third of all metastatic ER-positive breast cancer patients harbor *ESR1* mutations (8). Y537S and D538G are the two most commonly mutated residues in the LBD of $ER\alpha$. Collectively, these two mutations account for over 70% of all *ESR1* mutations found in breast cancer patients (9). *ESR1* LBD mutations confer estrogen-independent growth and variable resistance to many endocrine therapies (10). The Y537S mutation, in particular, is associated with a higher degree of resistance to most endocrine therapies, among all *ESR1* LBD mutations (8, 10-12). The Y537S mutation drives super-enhancer-mediated transcriptional re-wiring of ER-positive breast cancer cells and is associated with worse clinical outcomes relative to other LBD mutations (8, 11). Therapeutic strategies that preferentially target *ESR1* mutations, particularly Y537S, remain an unmet clinical need.

In this study, we explore the therapeutic potential of bromodomain and extraterminal domain (BET) inhibition to target *ESR1* mutation-induced “transcriptional addiction” (11) in ER-positive breast cancer.

Results

ESR1 mutations confer estrogen-independent growth in vivo. To recapitulate the phenotypic characteristics of tumors from ER α -positive breast cancer patients harboring *ESR1* mutations in a pre-clinical model, we employed ER-positive MCF-7 cells that were genome edited using adeno-associated virus (AAV) technology to knock-in the two most common *ESR1* mutations, Y537S and D538G (13). The mutant allele frequency was 50% for both the mutants, suggesting heterozygous targeting (13). When grown in estrogen-depleted conditions, the mutant cells exhibited high expression levels of GREB1 protein (a marker of activation of ER signaling) and rapid growth. Under the same conditions, control cells harboring the wild-type *ESR1* showed no detectable expression of GREB1 protein and exhibited growth retardation (Fig. 1A-C). To recapitulate the estrogen-independent growth characteristics of *ESR1* mutant tumors *in vivo*, we stably transfected a luciferase reporter into MCF-7 cells harboring the wild-type or mutant (Y537S and D538G) *ESR1* and injected them subcutaneously into 6-8 week old ovariectomized, female Non-Obese Diabetic Severe Combined Immuno-Deficient (NOD-SCID) mice without exogenous β -estradiol supplementation. MCF-7 cells harboring *ESR1* mutations supported robust tumor growth, while the corresponding cells harboring wild-type *ESR1* failed to generate viable tumors (Fig. 1D-E). Exogenous estrogen supplementation

rescued the parental MCF-7 cells, which supported robust xenograft growth in these conditions (Fig. S1A). These findings were replicated in xenografts derived from T-47D cells harboring wild-type or mutant *ESR1*s (Y537S and D538G) (Fig. S1B). Thus, xenografts harboring *ESR1* mutations exhibited substantial growth advantage over those harboring wild-type *ESR1* in ovariectomized mice. Based on these findings, we conclude that our pre-clinical model faithfully recapitulates the phenotypic characteristics of tumors from breast cancer patients harboring *ESR1* mutations and represents an excellent model system for therapeutic studies.

To study *ESR1* mutation-induced global transcriptional changes, we carried out RNA sequencing (RNA-seq) of MCF-7 cells harboring the Y537S or D538G mutation and the corresponding control cells harboring the wild-type *ESR1* in both hormone-depleted and estradiol-stimulated conditions; these experiments were conducted with biological replicates. In hormone-depleted conditions, the mutant cells exhibited the expression signature of wild-type cells stimulated with β -estradiol, suggesting constitutive activation of ER signaling (Fig. S2A). Consistent with prior reports, in the absence of ligand, *ESR1* mutants also activated unique transcriptional programs distinct from wild-type cells stimulated with β -estradiol (11, 13). Overall, 592 genes were stimulated and 666 genes were repressed over 2-fold in the Y537S mutant cells (relative to wild type cells without β -estradiol stimulation), whereas 475 genes were stimulated and 607 genes were repressed over 2-fold in the D538G mutant cells (FDR <0.05) (Fig. 1 F-G and Table S1 and S2). Approximately 60% of stimulated genes and 50% of repressed genes in the mutant cells overlapped with the corresponding stimulated/repressed genes in the wild-

type cells treated with β -estradiol (Fig. 1 F-G). There was greater than 50% overlap between the two mutant cells for both stimulated and repressed genes (Fig. S2B).

Pharmacological BET inhibition disrupts *ESR1* mutant-driven transcriptional programs. BRD4 is a member of BET family proteins and mediates super-enhancer-driven addiction of tumor cells to oncogenic drivers in a context-dependent fashion (14, 15). Pharmacological BET inhibition promotes loss of BRD4 at super-enhancers and preferentially disrupts transcription of super-enhancer-associated genes (16). Numerous small molecule BET inhibitors are currently in early phase clinical trials for treatment of various solid and hematologic malignancies (17). We have previously identified ER α as a binding partner of BRD4 in an unbiased screen of candidate cellular proteins interacting with BRD4 (18). We have also established an essential function for BRD4 in the regulation of ER α -induced gene expression by mediating elongation-associated phosphorylation of RNA polymerase II (19). Since *ESR1* mutations drive super enhancer-mediated transcriptional reprogramming in ER-positive breast cancer cells (11), we hypothesized that the transcriptional activity of *ESR1* mutants is likewise dependent on BRD4. To address this question, we first asked if mutant ER α proteins physically interact with BRD4. Using immunoprecipitation, we demonstrate that BRD4 was able to pull down ectopically expressed wild-type, Y537S and D538G ER proteins *in vivo* (Fig. 2A-B). Casein Kinase II-mediated phosphorylation of N-terminal cluster of Phosphorylation Sites (NPS) is critical for binding of BRD4 to acetylated chromatin and recruitment of sequence-specific transcription factors to gene promoters (Fig. 2A) (18). Consistent with this, an NPS deletion construct of BRD4 failed to effectively pull down both the wild-type and mutant ER α proteins, suggesting that NPS is crucial for BRD4 interaction with wild-type and

mutant ER α proteins (Fig. 2B). Furthermore, OTX015, a small molecule BET inhibitor (20, 21), disrupted the native BRD4-ER α interaction in MCF7 Y537S cells (Fig. 2C). Since these cells express both wild-type and mutant (Y537S) ER α proteins (13), our data suggest that OTX015 disrupts both these interactions. In summary, wild-type and mutant ER α proteins both physically interact with BRD4 and pharmacological BET inhibition disrupts this interaction. Next, we used RNA-seq analysis to study gene expression changes associated with disrupting mutant (Y537S and D538G) ER α -BRD4 interaction with OTX015. Treatment of MCF-7 cells with OTX015 reversed the transcriptional programs mediated by the Y537S and D538G mutations. Thus, in Gene Set Enrichment Analyses (GSEA), genes involved in early and late ER α response and MYC targets, which were the top positively enriched signatures in *ESR1* mutant cell lines, were the top negatively enriched signatures following OTX015 treatment (Fig. 2D-G and S3). These findings suggest that BET inhibition disrupts the transcriptional programs driven by *ESR1* mutations.

OTX015 is one of the top inhibitors of ESR1 mutant cells relative to drugs in the Prestwick chemical library. We next sought to benchmark the growth inhibitory effects of OTX015 in *ESR1* mutant cells against a large library of mostly FDA-approved drugs. For this purpose, we employed the Prestwick chemical library, a collection of 1,280 compounds, approximately 90% of which are FDA-approved drugs, in a primary screen against MCF-7 Y537S and D538G cell lines. Many cytotoxic and non-cytotoxic drugs clinically used to treat breast cancer such as docetaxel, cyclophosphamide, tamoxifen, anastrozole and fulvestrant are represented in this drug library. The screening window coefficient (Z' -factor) was used to optimize assay conditions (22). Cells were plated in

384-well format and after incubating the assay plates overnight, one drug per well was added to each plate to a final compound concentration of 3 μ M. After an incubation period of 96 hours, Cell Titer Glo™ reagent (Promega, Inc.) was added to each well and luminescence was measured. Z-scores were calculated from the corrected normalized activity for each compound (23). The assays for all cell lines displayed Z' values greater than 0.6, which is considered robust. A plot of activity of each library compound relative to OTX015 was generated. OTX015 emerged as one of the top hits in this primary screen against both the Y537S and D538G cell lines (Fig. 3A and S4). The top 30-40 hits from the primary screen were further validated in confirmatory studies in the wild-type as well as the two mutant cells in a multi-dose format with three replicates per compound per dose per cell line. OTX015 emerged as one of the top 2 hits against the Y537S mutant cells and among the top 10 hits against the D538G mutant cells (Fig. 3B and S4B). To determine if OTX015 has preferential activity against the *ESR1* mutant cells, we determined IC₅₀ of the drug in MCF-7 cells harboring the wild-type *ESR1* or Y537S/D538G mutations. While OTX015 exhibited similar activity against both the wild-type and D538G cells, it showed ~3-fold higher selectivity against the Y537S cells relative to both the wild-type and D538G cells (Fig. 3C). To test the generalizability of our findings, we evaluated the growth inhibitory effects of three small molecule BET inhibitors, OTX015, JQ-1 and I-BET762, against both MCF-7 and T-47D cells harboring the wild type or mutant (Y537S or D538G) *ESR1*. All BET inhibitors exerted growth inhibitory effects against MCF-7 and T-47D cells harboring both wild type *ESR1* and Y537S/D538G mutations. OTX015 and JQ-1 exhibited preferential activity against both MCF-7 and T-47D cells harboring *ESR1* Y537S mutation relative to those harboring wild type *ESR1* or

D538G mutation (Fig 3D). I-BET762 was less potent than both OTX015 and JQ-1 but retained preferential activity against Y537S mutant T-47D cells and a trend towards higher selectivity against Y537S mutant MCF-7 cells relative to the corresponding cells harboring the wild type *ESR1* or D538G mutation (Fig. 3D). In contrast, tamoxifen, a selective ER α modulator, was completely inactive against both MCF-7 and T-47D cells harboring Y537S and D538G mutations, although it inhibited the growth of corresponding cells harboring the wild-type *ESR1* (Fig. 3D).

OTX015 inhibits tumor growth in cell line and patient-derived xenografts harboring ESR1 Y537S mutation. Since Y537S mutation status is associated with a higher degree of resistance most endocrine therapies relative to other *ESR1* LBD mutations (8, 10-12), we sought to evaluate the *in vivo* therapeutic efficacy of OTX015 in xenograft models harboring *ESR1* Y537S mutation. As a first step, we performed pharmacokinetic (PK) studies to determine a dosing regimen for OTX015 in mice that affords drug exposure comparable to human clinical studies (20, 21). A Phase Ib study of OTX015 suggested 80 mg once daily with continuous dosing as the recommended dose and schedule for future human efficacy studies (20). Evaluation of human pharmacokinetics (PK) at this dose reveal a C_{max} of 1529 $\mu\text{g/L}$ and an AUC of 11,360 $\mu\text{g}\cdot\text{hr/L}$. An earlier Phase I study showed similar results, but they also reported trough values of 165 nM at the same dose (21). In an effort to mimic human exposures in our mouse model, we first evaluated the PK of OTX015 in mice administered orally at 50 mg/kg. Although our sampling was limited, our data at this dose revealed a similar C_{max} to the human data but lower AUC (Fig. S5). In order to more closely mimic total exposure and keep trough values closer to

human values, we elected to dose mice once daily with 100 mg/kg. Prior pre-clinical studies employing OTX015 have also used this dosing regimen (24).

To evaluate the *in vivo* efficacy of OTX015, we injected MCF-7 Y537S cells subcutaneously into the flank of 4-6 week old ovariectomized, athymic nude mice. Mice did not receive exogenous β -estradiol supplementation. When tumors reached a volume of 150-200 mm³, mice were randomized to vehicle, OTX015 (100 mg/kg daily as oral gavage, 6 days/week), fulvestrant (1 mg as subcutaneous injection weekly) or OTX015 + fulvestrant. OTX015 inhibited tumor growth and demonstrated higher efficacy than fulvestrant as a single agent. Combination of OTX015 with fulvestrant did not significantly improve tumor control (Figure 4A). The efficacy of OTX015 as a single agent was further validated in a previously characterized patient-derived xenograft harboring *ESR1* Y537S mutation (WHIM20) (25). NOD-SCID mice bearing this xenograft supported estrogen-independent tumor growth, and OTX015 exhibited potent activity in inhibiting tumor growth as a single agent (Fig. 4B). OTX015 treatment suppressed mRNA expression levels of *GREB1*, an ER responsive gene, in WHIM20 xenografts, suggesting effective target engagement of the drug *in vivo* (Fig. 4C). We have previously reported optimization of patient-derived explant (PDE) models of hormone-driven cancers to evaluate drug responses in an *ex vivo* environment, which retains the native tissue architecture and microenvironment of human tumors (26, 27). We adopted this model to evaluate the efficacy of three BET inhibitors against explants derived from WHIM20 (Fig. 4D). All BET inhibitors evaluated, which included OTX015, JQ-1 and I-BET762, exerted greater than 50% inhibition in explant proliferation, as measured by percentage of Ki-67 positive cells relative to vehicle treatment (Fig. 4E-F). Thus, our findings show that BET inhibitors, as

a class, inhibit *ESR1* Y537S-driven breast cancer growth in *in vitro*, *ex vivo* and *in vivo* models.

OTX015 acts synergistically with abemaciclib in inhibiting the growth of MCF-7 cells and xenografts harboring ESR1 Y537S mutation. Clinically, CDK4/6 inhibitors are the preferred systemic therapy for the treatment of metastatic, ER-positive breast cancer patients who have become resistant to endocrine therapies, including through acquisition of *ESR1* mutations (28). Previous studies have shown that BET inhibition synergizes with CDK4/6 inhibitors in NUT midline carcinoma and triple negative breast cancer through aneuploidy-induced cell cycle arrest (29-31). To test if such synergy exists in the context of *ESR1* mutant breast cancer, we tested OTX015 in combination with abemaciclib, an approved CDK4/6 inhibitor (32) in MCF-7 Y537S cells (Figure 5A-J). For these studies, we used the Bliss independence model to evaluate synergy, and we have observed synergy for the abemaciclib/OTX015 combination (synergy score = 1.91) compared to the sham controls for OTX015 (synergy score = 0.6) and abemaciclib (synergy score = -0.435). Synergy was also observed for the abemaciclib/OTX015 combination in MCF-7 cells harboring the wild-type *ESR1* (synergy score = 2.2) (Fig. S6) and D538G mutation (synergy score = 1.56) (Fig. S7). To assess synergy *in vivo*, we evaluated the efficacy of OTX015 in combination with abemaciclib in ovariectomized, athymic nude mice bearing MCF-7 Y537S xenografts. After tumor implantation, mice were randomized to treatment with vehicle, OTX015 (100 mg/kg daily as oral gavage, 6 days/week), abemaciclib (50 mg/kg daily as oral gavage, 6 days/week), a combination of abemaciclib (50 mg/kg daily as oral gavage, 6 days/week) with fulvestrant (1 mg subcutaneous injection weekly) or a combination of abemaciclib (50 mg/kg daily as oral

gavage, 6 days/week) with OTX015 (100 mg/kg daily as oral gavage, 6 days/week). As expected, OTX015 prevented progression of tumors when used as a single agent (Fig. 5K). Combination of abemaciclib with fulvestrant induced 1.3-fold regression in average tumor size. Remarkably, combination of abemaciclib with OTX015 produced 3.5-fold regression in average tumor size and was statistically superior to abemaciclib + fulvestrant (Fig. 5K). These findings suggest that OTX015 synergizes with abemaciclib in the treatment of *ESR1* mutant, endocrine therapy-resistant breast cancer, both *in vitro* and *in vivo*, and is superior to the current standard of care treatment of combination of CDK4/6 inhibitor with fulvestrant. Thus, our study provides therapeutic rationale for evaluating this combination in future clinical trials.

Top genes overexpressed in ESR1 mutant cells are also overexpressed in tumors of patients harboring ESR1 mutations and inhibited by OTX015. To determine if the genes overexpressed in *ESR1* Y537S cells are also overexpressed in tumors from breast cancer patients harboring *ESR1* mutations, we integrated the RNA-seq data from our MCF-7 Y537S cells with previously reported transcriptomic data of tumors from *ESR1* mutant breast cancer patients (11). In this study, Jeselsohn et al. employed the Genotype-Tissue Expression (GTEx) dataset to exclude genes that were upregulated in the corresponding normal tissue of the metastatic site and generated transcriptomic profiles of genes upregulated in human breast tumors harboring *ESR1* LBD mutations relative to wild-type tumors (11). First, we identified the top 10 genes overexpressed in MCF-7 Y537S cells (relative to control cells harboring wild-type *ESR1*) based on fold change (FC) and false discovery rate (FDR) (Fig. 6A and Table S3). These included a combination of both estrogen-responsive genes and estrogen-independent genes (Fig.

6B). Remarkably, seven out of the top ten genes in Y537S cells were also overexpressed in human breast tumors with the corresponding *ESR1* mutation (Figure 6A) (11). Next, we focused our attention on evaluating the impact of OTX015 treatment on the expression of this subset of seven genes that were overexpressed in both the MCF-7 Y537S cells and tumors from breast cancer patients harboring the same mutation. In our RNA-seq analysis, six of these seven genes were inhibited by OTX015 (Fig. 6B). These findings reinforce the clinical relevance of the cellular and xenograft models employed in this study and demonstrate that OTX015 inhibits most of the top overexpressing genes in MCF-7 Y537S cells that are also overexpressed in *ESR1* mutant patient tumors(11). Next, we compared the effect of OTX015 treatment on all Y537S-stimulated genes (relative to wild-type cells) in MCF-7 cells (Group 1) versus genes whose expression was unaltered by the Y537S mutation in the same cells (Group 2). We used a two sided t-test to test the null hypothesis that average fold change in expression levels of genes in the two groups following OTX015 treatment is not different. OTX015 exhibited remarkable selectivity towards inhibition of genes that are overexpressed in MCF-7 cells harboring the Y537S mutation (p-value: 9.29e-154) (Table S4). These findings reinforce the view that OTX015 has high selectivity in transcriptionally targeting genes and pathways that are upregulated in the Y537S mutant cells.

OTX015 has preferential activity against Y537S cells and blocks clonal selection of Y537S mutation in competition studies. Previous pre-clinical and clinical studies have demonstrated that Y537S mutation status is associated with a higher degree of resistance to endocrine therapies used for treating ER-positive breast cancer, such as aromatase inhibitors, tamoxifen and fulvestrant, relative to other *ESR1* LBD mutations (4, 5, 8, 10-

12, 33). To our knowledge, drugs that preferentially target Y537S mutant cells have not been described. To investigate if the higher selectivity of OTX015 against the Y537S cells (relative to wild-type cells) results in a negative selection pressure against this mutation in competition studies, we mixed 6-8% of T-47D cells harboring homozygous knock-in of the D538G or Y537S mutation with wild type cells and treated them with vehicle, tamoxifen or OTX015. Tamoxifen treatment resulted in an approximately 9-fold and 7-fold reduction in overall number of D538G/WT and Y537S/WT cells, respectively. However, tamoxifen exerted a positive selection pressure on both mutant cells. Thus, the mutant fraction of D538G and Y537S increased to approximately 55% (from 6.3%) and 77% (from 7.5%), respectively (Fig. 7). These findings suggest that tamoxifen treatment accelerates emergence of *ESR1* mutation-induced endocrine therapy resistance by exerting a positive selection pressure on the mutant cells. OTX015, on the other hand, exerted nearly 3000- and 20,000-fold reduction in D538G/WT and Y537S/WT cells, respectively. OTX015 treatment led to lesser degree of enrichment of D538 mutation compared to tamoxifen (24.5% vs 55.1%). Remarkably, OTX015 treatment completely eliminated enrichment of Y537S mutation (7.5% before treatment vs. 4.85% after treatment with OTX015 vs. 77.2% after treatment with tamoxifen) (Fig. 7). Our data suggest that, while BET inhibition blocks the transcriptional function of both wild-type and mutant ER α proteins, it represents a preferential vulnerability for the Y537S mutation. These findings are consistent with our data from growth inhibition assays, which show that the IC₅₀ of OTX015 is ~3 fold more potent in Y537S cells relative to wild-type and D538G cells. While the mechanistic underpinnings for higher selectivity of BET inhibitors towards the Y537S mutant breast cancer cells remain to be elucidated, Brown and co-

workers have previously shown that Y537S mutation activates unique transcriptional programs relative to other *ESR1* mutations (and wild type cells cells stimulated with β -estradiol) (11). Thus, mutant ER was recruited to 35,000 DNA binding sites in MCF7 Y537S cells and to 11,371 sites in D538G mutant cells. Furthermore, ER binding sites gained in Y537S cells are more likely to occur in promoter regions relative to other cells. Finally, over 30% of super-enhancers found in the Y537S cells overlapped with mutant gained DNA-binding sites. Thus, Y537S mutant-driven transcriptional programs may be more reliant on super-enhancers than those driven by wild-type or D538G mutant ER proteins. These findings are consistent with our data, which show that Y537S mutation activates unique transcriptional programs relative to both D538G mutation and WT ER stimulated with estrogen (Figure 1 and S2). Since BET inhibition has higher selectivity for targeting super enhancer-driven transcriptional programs (14), this may explain the preferential activity of OTX015 towards Y537S cells.

This finding has significant clinical relevance as the Y537S mutation status is associated with the higher degree of resistance (relative to other *ESR1* LBD mutations) to nearly all endocrine therapies clinically used in the treatment of ER α -positive breast cancer, and development of drugs that preferentially target the Y537S mutation remains an acute unmet clinical need.

Discussion

Somatic mutations in the LBD of *ESR1* are one of the most common mechanisms of acquired resistance to endocrine therapies (34). *ESR1* mutations are found in nearly a third of all metastatic, ER-positive breast cancer patients and associated with worse

clinical outcomes, including overall survival (4, 5, 8, 33). *ESR1* mutations are also enriched in patients with localized breast cancer receiving neoadjuvant endocrine therapy (35). A recent study has shown that nearly a third of locoregional recurrent tumors in patients who have completed definitive treatment for ER-positive breast cancer also harbor *ESR1* mutations (36).

In biochemical studies, the Y537S mutation exhibits the highest degree of transcriptional activity, phosphorylation and estrogen-independent growth relative to all other LBD mutations (10). In *in vivo* studies, the Y537S mutation also confers a greater degree of resistance to both tamoxifen and fulvestrant (10, 11). Consistent with these findings, Y537S mutation status is associated with worse overall survival relative to other *ESR1* LBD mutations (8). Furthermore, in large clinical studies such as the PALOMA-3 trial, there was significant enrichment for Y537S mutation at the end of treatment in both fulvestrant + placebo and fulvestrant + palbociclib arms relative to day 1. No such enrichment was found for the remaining 12 *ESR1* mutations evaluated in this study. While more definitive studies are needed, these findings suggest that Y537S mutation status is associated with resistance to both fulvestrant as a single agent and combination of fulvestrant with palbociclib (12). Similarly, in BOLERO-2 trial, although patients with both the wild-type and D538G mutation showed a significant improvement in progression-free survival with addition of everolimus to exemestane, patients harboring the Y537S mutation did not derive any benefit (although the sample size for this subgroup was modest to draw a definitive conclusion) (8). Taken together, retrospective analyses of clinical outcomes from PALOMA-3 and BOLERO-2 trials suggest that the Y537S mutation status may be associated with higher degree of resistance to both single agent endocrine

therapies as well as to combination regimens of endocrine therapies with palbociclib and everolimus. However, more definitive studies are needed to establish the role of Y537S mutation in conferring resistance to non-endocrine therapies such as palbociclib and everolimus. Nevertheless, while a number of novel therapeutics with improved efficacy against *ESR1* mutant breast cancer are being developed, to our knowledge drugs with preferential activity against the Y537S mutant tumors have not been described.

Many drugs that show promise in pre-clinical models often fail to afford meaningful clinical benefit in patients. Some key reasons for this high rate of failure include: using pre-clinical models of breast cancer that are not clinically relevant, inability to match the right drug to the right patient due to lack of predictive biomarkers, failure to identify rational drug combinations that enhance the clinical utility of the drug, unfavorable pharmacokinetic profile and unfavorable toxicity profile. In this study, we employ clinically-relevant models of breast cancer that faithfully recapitulate phenotypic characteristics of tumors from patients with treatment-resistant breast cancer. We match these cellular models with a patient-derived xenograft (PDX) that have the same phenotypic and molecular characteristics to perform mechanistic and therapeutic studies. Using a combination of biochemical and genomic studies, we show that both Y537S and D538G mutant proteins physically interact with BRD4. Treatment of these cells with OTX015, a small molecule BET inhibitor, reverses the transcriptional programs induced by the mutants. By benchmarking its activity against the Prestwick chemical library, we show that OTX015 is one of the top inhibitors of Y537S and D538G mutant breast cancer cells among a large collection of nearly 1200 FDA-approved drugs. By performing careful pharmacokinetic studies, we selected drug exposures that are easily achievable without significant adverse

effects in patients (based on human data from two Phase I clinical trials of OTX015). In cell line and patient-derived xenograft models, OTX015 showed efficacy as a single agent in suppressing tumor growth. Furthermore, OTX015 exhibits synergy when combined with CDK4/6 inhibitor, abemaciclib, and induced higher tumor regression than the current standard-of-care regimen of abemaciclib + fulvestrant. Thus, our findings support clinical evaluation of this drug combination in future BET inhibitor trials. By integrating the RNA-seq data from the MCF-7 Y537S cell lines with transcriptomic data of ER-positive tumors from breast cancer patients harboring the same *ESR1* mutation (11), we show that many of the top genes overexpressed in the mutant cell line are also overexpressed in patient samples and are targeted for inhibition by OTX015. We also show that transcriptional programs activated by Y537S mutation confer preferential vulnerability to BET inhibition. Thus, the IC₅₀ of OTX015 was ~3-fold more potent for Y537S cells relative to both wild-type and D538G cells. Consequently, in *in vitro* evolution experiments, OTX015 treatment completely blocks enrichment of Y537S mutant cells while tamoxifen treatment results in profound enrichment of these cells. Our findings uncover BET inhibition as a selective vulnerability for *ESR1* Y537S, a mutation associated with a higher degree of resistance to nearly all clinically approved endocrine therapies. Although a number of novel therapeutics with improved efficacy against *ESR1* mutant breast cancer are being developed, to our knowledge OTX015 is the only drug with preferential activity against the Y537S mutant breast cancer cells. Thus, our findings support evaluation of Y537S mutation as a predictive biomarker for response in ongoing BET inhibitor trials in ER-positive breast cancer. Based on their preferential activity against Y537S mutant breast cancer cells, we hypothesize that BET inhibitors may prevent or delay development of

Y537S-mediated endocrine therapy resistance and disease recurrence when used in the adjuvant setting for treatment of patients with localized, ER-positive breast cancer. This hypothesis needs to be validated in future clinical studies.

Numerous small molecule BET inhibitors are currently in early phase clinical trials for treatment of various solid and hematologic malignancies(17). While no efficacy data of BET inhibitors in breast cancer are currently available, a combined Phase I/II dose escalation and expansion study of BET inhibitor, GSK525762, in metastatic ER-positive breast cancer patients is currently underway (ClinicalTrials.gov Identifier: NCT02964507). OTX015 has shown a favorable safety profile in Phase I clinical trials (20, 21). At the recommended 80 mg once daily continuous dosing schedule for future human efficacy studies, reversible thrombocytopenia (16% of patients) and elevation of ALT/hyperbilirubinemia (5% of patients) were the major dose-limiting toxicities observed in the study. Other treatment-related adverse effects were primarily gastrointestinal in nature (diarrhea, nausea, vomiting and decreased appetite). Overall, the drug was well tolerated and toxicity profile is comparable to other non-endocrine targeted therapies in breast cancer such as CDK4/6 inhibitors (37). While these toxicities were reversible and did not impact tolerance in patients, novel synergistic combinations that allow de-escalation of BET inhibitor dose while maintaining or improving efficacy may further minimize toxicity in patients. Interestingly, a combination of OTX015 and abemaciclib (the most potent of the three clinically approved CDK4/6 inhibitors) exhibited remarkable efficacy and superior tumor regression than current standard-of-care treatment of abemaciclib + fulvestrant. Our findings provide therapeutic rationale for evaluating this combination in future BET inhibitor clinical trials.

A new generation BET inhibitor, ABBV-744, targeting BD2 but not BD1 of BRD4 with significantly fewer platelet and gastrointestinal toxicities but retained efficacy has recently been described (38). Furthermore, with our recent report describing opposing functions of BRD4 protein isoforms in breast carcinogenesis (39), we have laid the foundation for developing therapeutic approaches for isoform-specific targeting of BRD4. Efforts are underway to define the role of BRD4 protein isoforms in mediating *ESR1* mutant-induced transcriptional dysregulation. We expect that these efforts will lead to development of isoform-specific BRD4 inhibitors with improved efficacy and safety relative to pan-BRD4 inhibitors. Thus, the field of BET inhibitors will continue to evolve; strong mechanism-based translational studies that identify predictive biomarkers for improved response (such as Y537S mutation status) and rational combination treatments (such as CDK4/6 inhibitors) that synergize with BET inhibition and increase response rates will determine the clinical success of this class of drugs for treatment of endocrine therapy-resistant breast cancer.

Methods

Cell culture

T-47D and MCF-7 cells were purchased from American Type Culture Collection (ATCC). T-47D cells were cultured in RPMI Medium (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) from Hyclone. MCF-7 cells were cultured in DMEM (Gibco) supplemented with 10% FBS. Cells were grown in a humidified incubator with 5% CO₂. Cells were assessed for their viability and counted with a Countess II FL Automated Cell Counter (Life Technologies, Gaithersburg, MD). Monthly mycoplasma screening was performed with Plasmotest (Invivogen).

Chemicals/Drugs

4-hydroxytamoxifen and β -estradiol were purchased from Sigma. β -estradiol pellets (0.17 mg, 2-week release) for subcutaneous implantation were purchased from Innovation Research of America. OTX015, JQ1, I-BET762, fulvestrant and abemaciclib were purchased from Abmole.

Generation of ESR1 mutant cell lines

Generation of genome-edited *ESR1* mutant MCF-7 cells has been previously described(13). *ESR1* mutant T-47D cell lines were generated by CRISPR-Cas9 editing. The Neon Transfection System was used for the delivery of a plasmid containing *ESR1*-targeting sgRNA (5'-GCCCCTCTATGACCTGCTGC-3'; cloned into pGL3-U6 plasmid at Bsal site), Cas9 expression plasmid (Addgene 44758) and single-stranded oligonucleotide donor templates into T-47D cells following manufacturer guidelines. Successfully targeted cell clones were selected by treatment with 50 nM fulvestrant and genotyped using digital PCR (dPCR) (see below). Competition experiments were conducted by mixing parental T-47D cells with T-47D cells with mutant *ESR1* allele(s) of interest. Cell mixtures were grown for 5 weeks in the presence of DMSO, tamoxifen (1 μ M) or OTX015 (1 μ M). A portion of the cell population was harvested each week to measure changes in mutant allele frequency by dPCR.

Analysis of ESR1 mutations by dPCR

A duplex digital PCR assay was developed to detect wild-type *ESR1* allele and two hotspot *ESR1* mutations, p.D538G or p.Y537S. The duplex assay included a TET conjugated Locked Nucleic Acids (LNA)-modified DNA-oligonucleotide probe that

recognized the wild type *ESR1* allele (5'-T+C+T+AT+G+A+CCTG-3') and FAM conjugated LNA probe targeting either p.D538G (5'-CTA+T+G+GCC+TGC-3') or p.Y537S (5'-CCC+TC+T+C+TG+ACCT-3'). The probes were synthesized by IDT (Integrated DNA Technology, San Jose, CA). Specificity of these probes has been validated previously (40). The 20 µl dPCR assay mixture contained 10 µl of 2x dPCR Supermix for Probes (No dUTP), 0.9 mmol/L of forward (5'-GTCTTCCCACCTACAGTAACAAAGG-3') and reverse (5'-CTAGTGGGCGCATGTAGGC-3') primers, 0.25 mmol/L of respective probes, and approximately 100 ng of genomic DNA. dPCR assays were performed on the QX200 platform outfitted with an automated droplet generator (Bio-Rad). After droplet generation, the reactions were subjected to PCR amplification in a thermocycler (Bio-Rad, Hercules, CA). The PCR cycling parameters were 10 min at 95 °C followed by 40 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 2 min with 2 °C/s ramp at all steps. After PCR amplification, the emulsion was transferred to the QX200 instrument (Bio-Rad) to measure the end-point fluorescence signal in each droplet. The dPCR data were analyzed using QuantaSoft software version 1.7.4.0917 (Bio-Rad). Two-dimensional (FAM and HEX intensity) plots were made for each sample and "gates" were used to define graphical areas with specific fluorescence properties. The number of droplet events specific for wild-type or mutant *ESR1* alleles was used to calculate the mutation frequency.

D538G_ssDNA:

GGCTAGTGGGCGCATGTAGGCGGTGGGCGTCCAGCATCTCAAGCAGCAGGCCAT
AGAGGGGCACCACGTTCTTGCACCTTCATGCTGTACAGATGCTCCATG

Y537S_ssDNA

TAGTGGGCGCATGTAGGCGGTGGGCGTCCAGCATCTCAAGCAGCAGGTCAGAGA
GGGGCACCACGTTCTTGCACTTCATGCTGTACAGATGCTCCATGCCT

Hormone depletion and RNA-Seq

For hormone depletion, cells were cultured in phenol red-free tissue culture medium, IMEM, (GIBCO Cat# A10488-01) supplemented with 5% charcoal-dextran-treated calf serum (Valley Biomedical Cat# BS3050) and 2% penicillin-streptomycin in T150 flask. Hormone depletion was carried over 3 days by washing the cells with phenol red-free IMEM without serum (5 washings daily, 1 hour apart). At completion of washings each day, cells were re-cultured in phenol red free-IMEM supplemented with 5% charcoal-dextran-treated calf serum. On day 4, the cells were trypsinized and 1×10^6 cells were seeded on 10-cm culture dish. After overnight culture, cells were treated with vehicle, 10 pM β -estradiol, or 1 μ M OTX015 for 24 hours. The cells were then harvested and total RNA was extracted using RNeasy Mini Kit (QIAGEN) according to the manufacturer's instructions. RNA quantity and purity was measured by a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific), and integrity was analyzed by an Agilent Bioanalyzer 2100 (Agilent Technologies). RNA-seq libraries were prepared using Illumina TruSeq Standard mRNA Sample Preparation Kit (Illumina) according to the manufacturer's protocol. Libraries were validated on an Agilent Bioanalyzer 2100. RNA-seq libraries were sequenced on a SE75 (single end 75 base pair) NextSeq500 flow cell. The accession number for RNA-seq data is GEO: GSE206185.

RNA-seq analysis

Reads with phred quality scores less than 20 and less than 35 bp after trimming were removed from further analysis using trimgalore (v0.4.1). Quality-filtered reads were then aligned to the mouse reference genome GRCh38 (hg38) using the HISAT (v 2.0.1) aligner(41) using default settings and marked duplicates using Sambamba (v0.6.6)(42). Aligned reads were quantified using 'featurecount' (v1.4.6) (43) per gene ID against GENCODE v25 (44). Differential gene expression analysis was done using the R package edgeR (v3.10.5) (45). Cutoff values of absolute fold change greater than 2.0 and FDR \leq 0.05 were then used to select for differentially expressed genes between sample group comparisons. GSEA was assessed on DEGs to the Hallmark (H, v5.1) curated gene set from Molecular Signature Database. FDR of 0.2 or less was considered statistically significant for GSEA analysis (46). Top ranking genes in MCF-7 Y537S cells were nominated based on False Discovery Rate (FDR) and fold-change (relative to the expression of same genes in MCF-7 cells harboring wild-type *ESR1*). Ranking was created using the following formula: $-\log_{10}(\text{FDR}) * \log_2(\text{Fold-change})$ (47).

Cell growth assays

For cell growth assays, cells were cultured in phenol red-free tissue culture medium, IMEM, (GIBCO Cat# A10488-01) supplemented with 5% charcoal-dextran-treated calf serum (Valley Biomedical Cat# BS3050) and 2% penicillin-streptomycin in T150 flask. Where indicated, hormone depletion was carried over 3 days as described in the previous section. On day 4, cells were trypsinized and 1×10^4 cells were seeded in 6-well tissue culture plate and allowed to grow in an incubator for 6 days. On day 6, cells were washed, fixed with 4% paraformaldehyde, stained with 0.5% crystal violet solution for 20 minutes, washed with water and air dried. After photographic images of the plates were obtained,

the crystal violet was solubilized with 20% acetic acid and absorbance was measured at 490 nm using a Spark 10M multimode microplate reader (Tecan).

Immunoprecipitation and Immunoblotting

MCF-7 cells were transfected with FLAG-BRD4 and HA-ER α (wild-type, Y537S or D538G). 48 hours post-transfection, cells were homogenized in modified RIPA lysis buffer containing 50 mM Tris-HCl pH 7.5, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, complete protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche). Immunoprecipitation was performed with mouse anti-FLAG antibody (Sigma, cat# F3165), resolved by SDS-PAGE, and transferred onto a PVDF membrane. The membranes were immunoblotted with antibodies against HA (Cell Signaling Technology, cat# 3724) and anti-FLAG (Sigma, cat# F3165). Immunoreactive proteins were detected using ECL super signal west femto substrate reagent (Thermo Scientific). For endogenous immunoprecipitation and immunoblotting experiments, similar protocol was employed in native MCF-7 Y537S cells and immunoprecipitation and immunoblotting was performed with antibodies against endogenous ER α (Cell Signaling Technology, cat# 8644) and BRD4 (Cell Signaling Technology, cat# 13440).

High Throughput Drug Screen and cytotoxicity assays

Primary screening was conducted with the MCF-7 D538G and MCF-7 Y537S cells using a standard protocol (48). Specifically, cells were harvested, counted, and then plated to a final density of 600 cells per well in 60 μ l of medium in 384 well microtiter plates (#3707, Corning, Inc.) using a BioTek MultiFlo dispenser (BioTek, Inc.). After incubating the assay plates overnight in DMEM medium (Thermo-Fisher, Inc.) in 10% FBS (Atlanta Biologicals,

Inc.), the Prestwick Collection (1,280 drugs; Prestwick Chemical, Inc.) were added to each plate to a final compound concentration 3 μ M (1 replicate per compound, 0.6% DMSO) using a BioMek FX liquid handler (Beckman, Inc.). In confirmation studies, MCF-7 cells harboring the *ESR1* wild-type, Y537S and D638D were tested individually in a multi-dose format (doses: 3, 1, and 0.37 μ M with three replicates per compound per dose per cell line). For both primary screen and confirmatory studies, Cell Titer Glo™ reagent (Promega, Inc.) was added to each well (10 μ L of a 1:2 dilution in PBS/Triton X-100 [1%] final) and mixed after an incubation period of 96 hours under growth conditions. Plates were incubated for 10 minutes at room temperature and luminescence was determined for each well using an EnVision multi-label plate reader (Perkin-Elmer, Inc.). The assays for all three cell lines typically displayed Z' values greater than 0.6 (22).

In Vitro Drug Combinations Experiments with ESR1 Wild-type (WT) and Mutant Cell Lines

Pair-wise drug combinations experiments with OTX015 and abemaciclib were conducted with the MCF-7 cell line (*ESR1* WT) and two *ESR1* mutant MCF7 cell lines, each carrying either the D538G or Y537S mutation. Cells from all three cell lines were harvested, counted, and then plated to a final density of 600 cells per well in 50 μ L of medium in 384 well microtiter plates (#3707, Corning, Inc.) using a BioTek MultiFlo dispenser (BioTek, Inc.). After incubating the assay plates overnight in DMEM medium (Thermo-Fisher, Inc.) in 10% FBS (Atlanta Biologicals, Inc.) at 37°C in a 5% CO₂ atmosphere, these drugs were added to each plate to a final compound concentration that ranged from 2.7E-6M to 3.99E-9M (three replicates per combination per dose per cell line, 0.3% DMSO final) by Labcyte Echo 655 acoustic dispenser (Beckman, Inc.) utilizing a dose-response matrix design combination program where all the possible dose combinations for a drug pair can

be tested. Sham controls (e.g. OTX-15 vs OTX-15 and abemaciclib vs abemaciclib) were included for each cell line, which should be additive in the absence of any systematic plate errors. Cell Titer Glo™ reagent (Promega, Inc.) was added to each well (10 µL of a 1:2 dilution in PBS/Triton X-100 [1%] final) and mixed after an incubation period of 96 hours under growth conditions. Plates were incubated for 10 minutes at room temperature and luminescence was determined for each well using an EnVision multi-label plate reader (Perkin-Elmer, Inc.).

Analysis of High Throughput Screening data and Drug Combinations Studies

The Genedata Screener® software (version 16, GeneData, Inc. Basel, Switzerland) was used to process and analyze the screening data for small molecules. For analysis of the data from the primary screen of the UTSW chemical library, experimental results obtained from EnVision multi-label plate reader were processed using the Assay Analyzer module of the Genedata Screener® Suite. For each plate, the raw data values for all wells were normalized using the following equation, which assumes hits are infrequent, structurally unrelated, and randomly distributed on individual library plates:

$$\text{Normalized Values} = (\text{Raw Values} - \text{Median of Test Population}) / (\text{Median of Test Population}) * 100(48).$$

This assumption proved true for all the library plates. The Test Population consists of the UTSW library located in columns 3 to 22 of the 384-well assay plate. A positive control (3 µM OTX final concentration in column 1) was included on every assay plate as was a neutral control (DMSO only, columns 2 and 23), and untreated cells were at column 24. Normalized well values were then corrected, where a correction factor for each well was

calculated using a proprietary pattern detection algorithm in the Assay Analyzer software. Z-scores were calculated from the corrected normalized activity for each compound (23). For confirmation studies, the top 30-40 hits from the primary screen were selected and each compound was assayed in triplicate at the doses described above and the data for each assay well was normalized to the neutral controls. For each compound, the normalized activity values were condensed to a single value (condensed activity) using the "Robust Condensing" method in Genedata Screener®. The condensed activity is the most representative single value of the triplicates. In general, the triplicates were pre-condensed into a pair of values as follows: $Values(X,Y) = (\text{Median of Triplicates } m) \pm \text{Dispersion}$, where $\text{Dispersion} = \text{Median}(|X_1 - m|, |X_2 - m|, |X_3 - m|)$. The less X and Y differ ($|X - Y|$), the better the data quality. For data points where $|X - Y| \leq 30\%$, the median of X and Y was used as the condensed activity, which is also the median of the triplicate measurements. Otherwise, a condensing function $\text{Min}(X,Y)$ was used to estimate the condensed activity. Curve fitting for IC_{50} s was performed using Smart Fit method in Analyzer module of Genedata Screener® (V.15) software suite as previously described(49).

Pairwise drug combinations experiments were analyzed as described previously(50). In brief, data files from the EnVision Multi-label Plate Reader (Perkin-Elmer, Inc.) were loaded into the Genedata Analyzer™ software (Version 16.0, Genedata Inc.) and normalized as described above. Combinations data were analyzed with the Compound Synergy Extension module and synergy scores and combination indices were computed using the methods of Lehar et. al. (51) and Chou-Talalay (51, 52). In both cases, the Loewe, Bliss, and highest single agent (HSA) models of synergy were evaluated.

Pharmacokinetic studies

Mice were dosed with 50 mg/kg OTX015 formulated in 10% ethanol, 0.1% Tween 80 (Sigma) and 0.5% methylcellulose (Sigma). Blood was collected from the submandibular vein and placed into a K2EDTA BD microtainer at 30, 60, and 240 minutes after dosing. Plasma was processed from the collected whole blood by centrifugation for 10 minutes at 9600xg. An equal volume of methanol containing 150 ng/ml tolbutamide internal standard was added to 0.1 ml of plasma to precipitate plasma protein and release bound drug. The supernatant was then analyzed by LC-MS/MS using an ABSciex (Framingham, MA) 4000QTRAP mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. The compounds were detected with the mass spectrometer in MRM (multiple reaction monitoring) mode by following the precursor to fragment ion transitions optimized for the instrument: OTX015 492.1 to 383.1 and tolbutamide 271.2 to 91.2. An Agilent (Santa Clara, CA) XDB C18 column (50 X 4.6 mm, 5 micron packing) was used for chromatography with the following conditions: Buffer A: dH₂O + 5 mM ammonium acetate, Buffer B: methanol; 0-0.25 min 2% B, 0.25-2.0 min gradient to 98% B, 2.0- 3.0 min 98% B, 3.0-3.5 min gradient to 2% B; 3.5 to 4.0 min 2% B. A value of 3-fold above the signal obtained in the blank plasma was designated the limit of detection (LOD). The limit of quantitation (LOQ), defined as the lowest concentration at which back calculation yielded a concentration within 20% of the theoretical value and above the LOD signal, which was 0.5 ng/ml. Pharmacokinetic parameters were determined using the non-compartmental analysis tool in Phoenix WinNonlin (Certara Corp., Princeton, NJ.) Sparse sampling was applied and a user defined time range from 60-240 min was used to determine Lambda Z for calculation of half-life. A linear trapezoidal linear interpolation

was used for calculation of area-under-the-curve (AUC). T_{max} and C_{max} were determined by visual inspection.

Xenograft studies

For β -estradiol-independent xenograft growth assays, MCF-7 cells harboring the wild-type, Y537S and D538G mutations and stably transfected with a luciferase reporter were suspended in 1:1 (volume) matrigel : DMEM (Fisher Scientific) to a final concentration of 5×10^7 cells/ml. 100 μ l cell-gel mixture was then injected subcutaneously into the flank of 6-8 week old ovariectomized, female NOD SCID mice (UT Southwestern Breeding Core). No exogenous β -estradiol supplementation was provided to mice. Xenograft growth was monitored by luciferase activity using IVIS Lumina (PerkinElmer Inc.) following ocular injection of 100 μ l of 5 mg/ml potassium luciferin (Gold Bio, LUCK-1G). The experiment was terminated at six weeks and final volumes of isolated tumors were calculated using the formula: volume = $[\pi/6 \times \text{larger diameter} \times (\text{smaller diameter})^2]$. For β -estradiol-independent xenograft growth assays using T-47D cells, a similar protocol was followed using ovariectomized female athymic nude mice. Following caliper measurements, tumor volumes were calculated as described above.

For therapeutic studies, 10 million MCF-7 Y537S cells or Y537S PDX (WHIM20) cell suspension in 1:1 (volume) matrigel : DMEM was injected subcutaneously into the flank of 6-8 weeks old, ovariectomized, female nude mice (Charles River) for cell line xenografts or NOD SCID mice (UT Southwestern breeding core) for PDX. No exogenous β -estradiol supplementation was provided to mice. When tumors reached a size of 100-200 mm³, the mice were randomized to various treatment arms as indicated. For synergy

studies, tumors were allowed to reach a size of 300-400 mm³ before they were randomized to one of the indicated treatment arms. The drug dosing schedule was as follows:

Vehicle oral gavage daily, 6 days/week; OTX015 (100 mg/kg) by oral gavage daily, 6 days/week; abemaciclib (50mg/kg) by oral gavage daily, 6 days/week and fulvestrant 1 mg by subcutaneous injection weekly.

Patient-derived explant studies

Patient-derived xenograft (PDX) model WHIM20 was established by direct engraftment of tumor fragments implanted via intra-mammary fat pad in SCID mice. Tumors were excised at 1000 mm³ and dissected into 2 mm cubes to be cultured *ex-vivo*. Explant was incubated on gelatin sponges for 48 hours in culture medium containing 10% FBS and 1% penicillin/streptomycin with either vehicle or 10 µM of OTX015, JQ1 or I-BET762. Explant tissue sample was fixed in 10% formalin at room temperature overnight and subsequently processed into paraffin blocks. For immunohistochemical studies, tissue sections were blocked in Background Sniper (Biocare Medical) followed by overnight incubation at 4 degrees with Ki-67 (1:500) primary antibody, followed by secondary antibody (1:1000) incubation for 60 minutes at room temperature. Immunoreactivity was visualized by using 3,3'-diaminobenzidine (DAB) (Vector Lab, Inc.). A proliferative index was calculated as the percentage of Ki-67-positive cells in three randomly selected microscopic fields at 40X per slide.

qRT-PCR

The frozen PDX tumors were ground in RNA extraction buffer and total RNAs was isolated using RNA extraction Kit (Sigma). For gene transcription analysis, cDNA synthesis was performed with 0.5-1 μ g total RNA of WHIM20 tumors using SuperScript III First Strand Synthesis System (ThermoScientific). qRT-PCR was perform in Bio-Rad CFX900 using SsoAdvanced™ Universal SYBR Green Supermix (BioRad). Primers of human GREB1, GAPDH were purchased from Sigma.

Sequences of primers were as the following:

GREB1 forward: 5'-GTGGTAGCCGAGTGGACAAT-3', reverse: 5'-
ATTTGTTTCCAGCCCTCCTT-3'.

GAPDAH forward: 5'-GTCTCCTCTGACTTCAACAGCG-3', reverse: 5'-
ACCACCCTGTTGCTGTAGCCAA-3'.

Statistics

Each experiment was performed with biological replicates as indicated. Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software). A two-sided Student's t test was used for comparison between experimental groups. For experiments that involved more than two groups, to adjust for multiple comparions, ANOVA with Dunnett's test was used to compare various experimental arms with the control arm. When comparing various treatment groups to each other, (non-parametric) Wilcoxon rank sum test with Bonferroni correction was used. A p value of 0.05 or less was considered statistically significant.

Study approval. All animal experiments were performed in accordance with UT Southwestern institutional animal care and use committee (IACUC) approved protocol.

Author Contributions

PGA and GPG conceptualized the study. SNU, QW, SK, SG, NSW, GPG, SW, BAP and PGA designed the study methodology. SNU, QW, SK, S-YW, SG, MH, KP and SW conducted experiments. SNU, QW, SK, VSM, SW, BAP, SG, NSW, YL, GVR, GPG and PGA interpreted data and/or performed statistical analysis. SNU, QW, SK, VSM, SG, NSW, YL, JS, BAP, RSM, SM, JML, GVR, RJ, MSW, BHP, GPG, AMC, C-MC and PGA contributed to the writing, review, and/or revision of the manuscript. PGA supervised the study.

Acknowledgements

This work was partially supported by Conquer Cancer Foundation of ASCO Young Investigator Award, DocStar Award from Cary Council of Southwestern Medical Foundation and US Department of Defense Breast Cancer Research Program Breakthrough Award (W81XWH-21-1-0112) to PGA, US Department of Defense Breast Cancer Research Program Breakthrough Award (W81XWH-21-1-0114), NIH grant R01CA245294 and Cancer Prevention and Research Institute of Texas (CPRIT) grant RP190454 to RSM, and NIH grant 1R01CA251698-01 and CPRIT grants RP180349 and RP190077 to C-MC. Drug screening and combination studies were carried out with an Echo 655, which was obtained by BP through a shared instrumentation grant (S10 OD026758-01) in 2019.

Conflict of interest statement: GPG is a scientific advisor with ownership interest in Naveris, Inc, and has received research Breakpoint Therapeutics and Merck. AMC is a scientific advisory board member and co-founder of Oncopia. MSW has financial holdings

and is a scientific advisor for OncoMed Pharmaceuticals and MedImmune. GVR is a patent holder and recipient of federal grants (NIH R01 CA223828, titled, "Therapeutic Agents Targeting Nuclear Receptor Signaling in Distinct Molecular Subtypes of Breast Cancer) on drugs targeting the estrogen receptor in breast cancer. The remaining authors declare that no conflicts of interest exist.

References:

1. Osborne CK. Tamoxifen in the treatment of breast cancer. *The New England journal of medicine*. 1998;339(22):1609-18.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *The New England journal of medicine*. 2005;353(17):1784-92.
3. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687-717.
4. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet*. 2013;45(12):1446-51.
5. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet*. 2013;45(12):1439-45.
6. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor- α mutations in pretreated advanced estrogen receptor-positive breast cancer. *Clin Cancer Res*. 2014;20(7):1757-67.
7. Zhang QX, Borg A, Wolf DM, Oesterreich S, and Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. *Cancer Res*. 1997;57(7):1244-9.
8. Chandralapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. *JAMA Oncol*. 2016;2(10):1310-5.
9. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *J Clin Oncol*. 2016;34(25):2961-8.
10. Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, et al. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. *Cancer Discov*. 2017;7(3):277-87.
11. Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. *Cancer Cell*. 2018;33(2):173-86 e5.

12. O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. *Cancer Discov.* 2018;8(11):1390-403.
13. Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, et al. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. *Breast Cancer Res.* 2017;19(1):60.
14. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell.* 2013;153(2):320-34.
15. Wu SY, and Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. *J Biol Chem.* 2007;282(18):13141-5.
16. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell.* 2013;24(6):777-90.
17. Stathis A, and Bertoni F. BET Proteins as Targets for Anticancer Treatment. *Cancer Discov.* 2018;8(1):24-36.
18. Wu SY, Lee AY, Lai HT, Zhang H, and Chiang CM. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. *Mol Cell.* 2013;49(5):843-57.
19. Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, et al. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. *Cell Rep.* 2014;8(2):460-9.
20. Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. *J Clin Oncol.* 2018;JCO2018782292.
21. Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, et al. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. *Clin Pharmacokinet.* 2015.
22. Zhang JH, Chung TD, and Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.* 1999;4(2):67-73.
23. Wu Z, Liu D, and Sui Y. Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings. *J Biomol Screen.* 2008;13(2):159-67.
24. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, et al. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. *Mol Cancer Res.* 2016.
25. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Rep.* 2013;4(6):1116-30.
26. Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, et al. A patient-derived explant (PDE) model of hormone-dependent cancer. *Mol Oncol.* 2018;12(9):1608-22.
27. Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, et al. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. *Eur Urol Oncol.* 2018;1(4):325-37.
28. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;17(4):425-39.

29. Liao S, Maertens O, Cichowski K, and Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETs and CDK4/6is. *Genes Dev.* 2018;32(17-18):1188-200.
30. Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovic B, et al. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. *Mol Cell.* 2020;78(6):1096-113 e8.
31. Ge JY, Shu S, Kwon M, Jovanovic B, Murphy K, Gulvady A, et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. *Nat Commun.* 2020;11(1):2350.
32. Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. *JAMA Oncol.* 2019.
33. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. *Sci Transl Med.* 2015;7(313):313ra182.
34. Alluri PG, Speers C, and Chinnaiyan AM. Estrogen receptor mutations and their role in breast cancer progression. *Breast Cancer Res.* 2014;16(6):494.
35. Leal MF, Haynes BP, Schuster E, Yeo B, Afentakis M, Zabaglo L, et al. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. *Clin Cancer Res.* 2019;25(24):7485-96.
36. Zundevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. *Breast Cancer Res.* 2020;22(1):16.
37. Marra A, and Curigliano G. Are all cyclin-dependent kinases 4/6 inhibitors created equal? *NPJ Breast Cancer.* 2019;5:27.
38. Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. *Nature.* 2020;578(7794):306-10.
39. Wu S-YL, C-F; Lai, H-T; Yu, C-T; Lee, J-E; Zuo, H; Tsai, S.Y; Tsai, M-J; Ge, K; Wan, Y; Chiang, C-M. Opposing Functions of BRD4 Isoforms in Breast Cancer. *Molecular Cell* 2020;78(6):1114.
40. Kumar S, Lindsay D, Chen QB, Garrett AL, Tan XM, Anders CK, et al. Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. *NPJ Breast Cancer.* 2018;4:39.
41. Pertea M, Kim D, Pertea GM, Leek JT, and Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. *Nat Protoc.* 2016;11(9):1650-67.
42. Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, and Prins P. Sambamba: fast processing of NGS alignment formats. *Bioinformatics.* 2015;31(12):2032-4.
43. Liao Y, Smyth GK, and Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923-30.
44. Mudge JM, and Harrow J. Creating reference gene annotation for the mouse C57BL6/J genome assembly. *Mamm Genome.* 2015;26(9-10):366-78.
45. Robinson MD, McCarthy DJ, and Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139-40.
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545-50.
47. Tusher VG, Tibshirani R, and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A.* 2001;98(9):5116-21.

48. Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. *Cell*. 2013;155(3):552-66.
49. Fomenko I, Durst M, and Balaban D. Robust regression for high throughput drug screening. *Comput Methods Programs Biomed*. 2006;82(1):31-7.
50. Witkiewicz Agnieszka K, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, et al. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. *Cell Reports*. 2016;16(7):2017-31.
51. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nat Biotech*. 2009;27(7):659-66.
52. Chou T-C, and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Advances in Enzyme Regulation*. 1984;22(0):27-55.




Figure 1. *ESR1* mutations confer estrogen-independent growth *in vivo*: (A-B) MCF-7 cells harboring wild-type or mutant (Y537S or D538G) *ESR1* were hormone-deprived for 3 days and plated at a density of 10,000 cells per well in a 6-well plate in triplicate. Cells were allowed to grow for 6 days and cell viability was quantified by crystal violet staining. (C) MCF-7 cells harboring wild-type or *ESR1* Y537S or D538G mutations were hormone-deprived for 3 days and lysates immunoblotted as indicated. (D-E) MCF-7 cells harboring wild-type, D538G or Y537S mutation and stably transfected with a luciferase reporter were injected subcutaneously (5 million cells/injection) in the flanks of ovariectomized, NOD-SCID mice ($n=6$ tumors) and allowed to grow without exogenous β -estradiol supplementation. Tumors were resected at the end of week 6 (D) and tumor volumes were quantified (E). Statistical significance was evaluated using ANOVA with Dunnett's test to adjust for multiple comparisons to wild-type sample. *** $p \leq 0.0005$. (F-G) Heat map showing differentially regulated genes in MCF-7 cells harboring D538G (F) or Y537S mutation (G) relative to cells harboring wild-type *ESR1* (Fold-change > 2 and FDR < 0.05) in hormone-depleted conditions. Also shown are Venn diagrams depicting overlap between upregulated/downregulated genes in β -estradiol-stimulated wild-type cells and hormone-depleted mutant cells as indicated.




Figure 2. Pharmacological BET inhibition disrupts *ESR1* mutant-driven transcriptional programs:

(A) Schematic depiction of domain architecture of full-length and a deletion construct of BRD4 lacking NPS. (BD1: bromodomain I, BD2: bromodomain II, BID: basic residue-enriched interaction domain, ET: extraterminal domain; NPS: N-terminal cluster of phosphorylation sites, CTM: C-terminal motif). (B) FLAG-tagged BRD4 (full-length or deletion construct lacking NPS) and HA-tagged wild-type, Y537S or D538G ERα were ectopically expressed in MCF-7 cells and nuclear extracts were subjected to immunoprecipitation using α-FLAG antibody and analyzed for the presence of ERα. (C) Nuclear extracts from MCF-7 Y537S cells were subjected to immunoprecipitation with BRD4 antibody and analyzed for the presence of native ERα following treatment with vehicle or OTX015 (1 μM). (D-G) GSEA of genes differentially expressed in MCF-7 Y537S (D) and D538G cells (E) relative to the wild-type cells showing activation of ERα signaling. GSEA of genes differentially expressed in MCF-7 Y537S (F) and D538G cells (G) following treatment with OTX015 showing suppression of ERα signaling.




Figure 3. OTX015 is one of the top inhibitors of *ESR1* mutant cells relative to drugs in the Prestwick chemical library: (A) A plot of relative activity of individual compounds in the Prestwick chemical library relative to OTX015 performed in MCF-7 Y537S cells. The screen was carried out at a drug concentration of 3 μ M in 384-well format. Cytotoxicity was assayed by luminescence using Cell Titer Glo™. (B) A plot of log IC₅₀ values of the top hits identified in the primary screen. Dose-response relationships for the top hits from the primary screen were established against the wild-type and the two mutant cells in a multi-dose format with three replicates per compound per dose per cell line. (C) Dose-response relationship curves for OTX015 against MCF-7 cells harboring *ESR1* wild-type, Y537S or D538G mutations. (D) MCF-7 or T-47D cells harboring wild-type or mutant (Y537S or D538G) *ESR1* were plated at a density of 10,000 cells per well in a 6-well plate in triplicate. Cells were treated with the indicated drug at 1 μ M concentration and allowed to grow for 6 days. Cell viability was quantified by crystal violet staining and data was plotted as fraction survival relative to vehicle treatment. Statistical significance was evaluated using ANOVA with Dunnett's test to adjust for multiple comparisons. *** $p \leq 0.0005$; ** $p \leq 0.005$; * $p \leq 0.05$; # $p \leq 0.05$ by unpaired t-test and NS by ANOVA with Dunnett's test




Figure 4. Pharmacological BET inhibition blocks growth of tumor xenografts harboring *ESR1* Y537S mutation: (A) MCF-7 Y537S cells were implanted subcutaneously into ovariectomized athymic, nude mice without exogenous β -estradiol supplementation. When tumors reached 150-200 mm³, mice were randomized (n=8 tumors/arm) and received vehicle, OTX015 (100 mg daily by oral gavage, 6 days/week), fulvestrant (1 mg sub-cutaneous injection weekly) or OTX015 + fulvestrant as indicated. (B) WHIM20 cells harboring Y537S mutation were implanted subcutaneously into ovariectomized, NOD-SCID mice without exogenous β -estradiol supplementation. When tumors reached 150-200 mm³, mice were randomized (n=6 tumors/arm) and received vehicle or OTX015 (100 mg daily by oral gavage, 6 days/week). The results were plotted as average tumor volume measured for each group \pm SEM. (C) RT-PCR for *GREB1* in WHIM20 xenografts (n=6) from vehicle and OTX015-treated mice. (D) Schematic representation of patient-derived xenograft explant assay. (E, F) WHIM20 explants (n=3) were treated with vehicle, OTX015, JQ-1 or I-BET762 at 10 μ M concentration for 48 hours and effect on proliferation was measured by Ki-67 immunohistochemistry staining. The quantification of the images was performed by the image analysis software ImageJ (Image Processing and Analysis in Java; Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA) and the results are shown as the ratio between the Ki-67-positive area and the total area of the image. p values were determined using an unpaired, two tailed t-test for pairwise comparisons. To correct for multiple comparisons, ANOVA with Dunnett's test was used to compare various experimental arms with the vehicle arm. Non-parametric Wilcoxon rank sum test with Bonferroni correction was used for comparing treatment groups to each other. * p \leq 0.05; ** p \leq 0.005; *** p \leq 0.0005.




Figure 6. Top genes overexpressed in MCF-7 Y537S cells are also overexpressed in tumors of patients harboring *ESR1* Y537S mutation and inhibited by OTX015. (A) A volcano plot depicting genes that are significantly up (red) or down-regulated (blue) in MCF-7 Y537S cells relative to wild-type cells based on log FC and FDR thresholds. The top 10 overexpressed genes in the MCF-7 Y537S cells were identified and labeled in the plot. Genes from this top 10 list that were also overexpressed in tumor samples from breast cancer patients harboring *ESR1* Y537S mutation (11) are highlighted with a green rectangle. (B) Expression levels of genes identified above following treatment of MCF-7 Y537S cells with vehicle or OTX015. Statistical significance was evaluated using ANOVA with Dunnett's test to correct for multiple comparisons to Y537S group. **** p < 0.0005; ** p < 0.005.




Figure 7. OTX015 suppresses growth of T-47D cells expressing *ESR1* Y537S mutation: (A) Schematic representations of competition-based growth analyses performed using mixtures of T-47D cells generated by spike-in of CRISPR-engineered D538G (upper panel, blue) or Y537S (lower panel, red) clones into the non-mutated parental T-47D cell line. Pre-treatment mutant allele frequency (MAF) was quantified by duplex digital PCR (dPCR), and total counts of mutant cell clones are also indicated. These cell line mixtures were cultured for 5 weeks in the presence of either DMSO, 1 μM Tamoxifen, or 1 μM OTX015. The endpoint allele frequencies for D538G (upper panels, blue) or Y537S (lower panels, red) and the total cell numbers of the mutant clones are indicated for the endpoint of the drug treatment study. Analysis of MAF and total cell counts were used to generate growth curves or cumulative population doublings for (B) *ESR1*-WT (black), (C) *ESR1*-D538G (blue), and (D) *ESR1*-Y537S (red) clones during exposure to DMSO (circles), 1 μM Tamoxifen (squares), or 1 μM (OTX015). Error bars indicate 95% confidence intervals for each time point. To correct for multiple comparisons, ANOVA with Dunnett's test was used to compare various experimental arms with the vehicle arm. Non-parametric Wilcoxon rank sum test with Bonferroni correction was used for comparing treatment groups to each other. **** $p \leq 0.0001$. Representative results from one out of three independent experiments are shown.